Developing Countries Vaccine Manufacturers Network

Source: Wikipedia, the free encyclopedia.

The Developing Countries Vaccine Manufacturers Network (DCVMN) is a voluntary non-partisan public health alliance of health organizations and vaccine manufacturers. It has the goal of protecting people globally against known and emerging infectious diseases through the provision of a consistent supply of high quality vaccines at affordable prices for developing countries, to achieve vaccine equity.[1][2][3] DCVMN includes manufacturers in Brazil, China, Cuba, India, Indonesia, Mexico, South Africa and other low and middle income countries (LMICs).[4] It was established in 2000[5]/2001,[6] and is headquartered in Switzerland.[5] As of 2021, the President is Sai D. Prasad,[7] and the CEO is Rajinder Suri.[8]

In 2018, DCVMN members supplied more than half of the 2.36 billion doses of vaccines used globally by UNICEF.[9] In 2019, a survey of 41 DCVMN members assessed their ability to use technology platforms, cell cultures and filling technologies for the manufacture of drug products. DCVMN members reported that they had the capability to supply over 50 distinct vaccines to 170 countries, totalling more than 3.5 billion vaccine doses annually.[10]

At least 15 manufacturer members have achieved WHO prequalification for their vaccines.[9] Members are developing and producing novel vaccines for illnesses including neglected tropical diseases:[11] rotavirus, Japanese encephalitis, pertussis,[12] haemophilus influenzae, hepatitis B,[13] hepatitis E, meningitis A,[3] cholera, poliovirus, human papillomavirus infection, dengue fever, Chikungunya virus and COVID-19.[10][14]

Developing countries that have the capacity for production of whole inactivated virus (WIV) and protein-based vaccines may be critical in addressing COVID-19 vaccine access gaps and achieving vaccine equity for LMICs.[4] As of 29 December 2020, 18 DCVMN members were involved in preclinical or clinical trials for possible COVID-19 vaccines, three of them in Phase III trials.[10] The DCVMN is a vaccine manufacturers partner of COVAX, a worldwide initiative for equitable access to COVID-19 vaccines.[15][16]

As of 2016, the timeline from a vaccine's first regulatory submission in its country of origin to its approval for use in Sub-Saharan Africa could take up to seven years.[17][18] The DCVMN is active in identifying obstacles in the processes of vaccine registration and use. It works to increase coordination of requirements and procedures to improve the prequalification, procurement and supply of vaccines. This can involve governments in different countries, the World Health Organization (WHO), and United Nations agencies such as UNICEF.[17][19][20]

The Developing Countries Vaccine Manufacturers Network has received funding from the Bill & Melinda Gates Foundation.[5]


  1. ^ "DCVMN". Developing Countries Vaccine Manufacturers Network. Retrieved 26 April 2022.
  2. ^ Poeloengan, Thamrin; Raw, Isaias; Martinez, Luis Herrera; El-Abbadi, Mohamed (12 November 2001). "Developing Country Vaccine Manufacturers Network (DCVMN), 26–27 April 2001, Bandung, Indonesia". Vaccine. 20 (3): 285–287. doi:10.1016/S0264-410X(01)00333-4. ISSN 0264-410X. PMID 11672886. Retrieved 26 April 2022.
  3. ^ a b Pagliusi, Sonia; Makhoana, Morena; Datla, Mahima; Leite, Luciana; Hendriks, Jan; Gholami, Alireza; Huang, Weidan; Gao, Yongzhong; Jadhav, Suresh; Harshavardhan, Gutla V. J. A.; Wu, Yonglin; Suhardono, Mahendra; Homma, Akira (28 June 2013). "Developing Countries Vaccine Manufacturers Network (DCVMN): engaging to step up for vaccine discovery and access. Meeting report 2012". Vaccine. 31 (31): 3111–3115. doi:10.1016/j.vaccine.2013.04.082. ISSN 1873-2518. PMID 23684836. Retrieved 26 April 2022.
  4. ^ a b Hotez, Peter J.; Bottazzi, Maria Elena (27 January 2022). "Whole Inactivated Virus and Protein-Based COVID-19 Vaccines". Annual Review of Medicine. 73 (1): 55–64. doi:10.1146/annurev-med-042420-113212. ISSN 0066-4219. PMID 34637324. S2CID 238747462.
  5. ^ a b c "Developing Countries Vaccine Manufactures Network (DCVMN) International". Devex. Retrieved 26 April 2022.
  6. ^ Hendriks, Jan; Blume, Stuart (7 July 2016). "Why might regional vaccinology networks fail? The case of the Dutch-Nordic Consortium". Globalization and Health. 12 (1): 38. doi:10.1186/s12992-016-0176-6. ISSN 1744-8603. PMC 4936226. PMID 27388678.
  7. ^ Mascarenhas, Anuradha (17 December 2021). "Great success in vaccine development, but inequity has to be addressed, says expert". The Indian Express. Retrieved 27 April 2022.
  8. ^ "Challenges and solutions to scaling-up COVID-19 vaccine manufacturing capacity". IFPMA. Retrieved 27 April 2022.
  9. ^ a b Hayman, Benoit; Pagliusi, Sonia (29 April 2020). "Emerging vaccine manufacturers are innovating for the next decade". Vaccine: X. 5: 100066. doi:10.1016/j.jvacx.2020.100066. ISSN 2590-1362. PMC 7242873. PMID 32462140.
  10. ^ a b c Hayman, Benoit; Dennehy, Maureen (23 August 2021). "Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization". Vaccine. 39 (36): 5153–5161. doi:10.1016/j.vaccine.2021.07.044. ISSN 1873-2518. PMC 8330991. PMID 34362602.
  11. ^ Jadhav, S.; Gautam, M.; Gairola, S. (May 2014). "Role of vaccine manufacturers in developing countries towards global healthcare by providing quality vaccines at affordable prices". Clinical Microbiology and Infection. 20: 37–44. doi:10.1111/1469-0691.12568. PMID 24476201. Retrieved 26 April 2022.
  12. ^ Pagliusi, Sonia; Leite, Luciana C.C.; Datla, Mahima; Makhoana, Morena; Gao, Yongzhong; Suhardono, Mahendra; Jadhav, Suresh; Harshavardhan, Gutla V.J.A.; Homma, Akira (April 2013). "Developing Countries Vaccine Manufacturers Network: Doing good by making high-quality vaccines affordable for all" (PDF). Vaccine. 31: B176–B183. doi:10.1016/j.vaccine.2012.11.060. PMID 23598479. Retrieved 27 April 2022.
  13. ^ Jadhav, Suresh; Datla, Mahima; Kreeftenberg, Hans; Hendriks, Jan (20 March 2008). "The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries". Vaccine. 26 (13): 1611–1615. doi:10.1016/j.vaccine.2008.01.034. ISSN 0264-410X. PMID 18294742. Retrieved 26 April 2022.
  14. ^ Pagliusi, Sonia; Jarrett, Stephen; Hayman, Benoit; Kreysa, Ulrike; Prasad, Sai D.; Reers, Martin; Hong Thai, Pham; Wu, Ke; Zhang, Youn Tao; Baek, Yeong Ok; Kumar, Anand; Evtushenko, Anatoly; Jadhav, Suresh; Meng, Weining; Dat, Do Tuan; Huang, Weidan; Desai, Samir (22 July 2020). "Emerging manufacturers engagements in the COVID −19 vaccine research, development and supply". Vaccine. 38 (34): 5418–5423. doi:10.1016/j.vaccine.2020.06.022. ISSN 0264-410X. PMC 7287474. PMID 32600908.
  15. ^ "Biotech, Developing and Developed Countries Vaccine Manufacturers COVID-19 Press Briefing (16 December 2021)". International Federation of Pharmaceutical Manufacturers and Associations. Retrieved 26 April 2022.
  16. ^ "COVAX Manufacturing Task Force to tackle vaccine supply challenges". GAVI. Retrieved 26 April 2022.
  17. ^ a b Dellepiane, Nora; Pagliusi, Sonia (21 May 2019). "Opportunities for improving access to vaccines in emerging countries through efficient and aligned registration procedures: An industry perspective". Vaccine. 37 (23): 2982–2989. doi:10.1016/j.vaccine.2019.03.025. ISSN 0264-410X. PMID 31027928. S2CID 135439603.
  18. ^ Ahonkhai, Vincent; Martins, Samuel F.; Portet, Alexandre; Lumpkin, Murray; Hartman, Dan (16 November 2016). "Speeding Access to Vaccines and Medicines in Low- and Middle-Income Countries: A Case for Change and a Framework for Optimized Product Market Authorization". PLOS ONE. 11 (11): e0166515. Bibcode:2016PLoSO..1166515A. doi:10.1371/journal.pone.0166515. ISSN 1932-6203. PMC 5112794. PMID 27851831.
  19. ^ Dellepiane, Nora; Pagliusi, Sonia (7 June 2018). "Challenges for the registration of vaccines in emerging countries: Differences in dossier requirements, application and evaluation processes". Vaccine. 36 (24): 3389–3396. doi:10.1016/j.vaccine.2018.03.049. ISSN 0264-410X. PMC 6278877. PMID 29724510.
  20. ^ Hayman, Benoit; Bowles, Alex; Evans, Beth; Eyermann, Elizabeth; Nepomnyashchiy, Lyudmila; Pagliusi, Sonia (22 February 2021). "Advancing innovation for vaccine manufacturers from developing countries: Prioritization, barriers, opportunities". Vaccine. 39 (8): 1190–1194. doi:10.1016/j.vaccine.2020.12.085. ISSN 0264-410X. PMC 7909323. PMID 33487466. Retrieved 26 April 2022.

External links